Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 3/20 | 0.34 |
| ▸ | BTK | Q06187 | 7/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 3/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18585909 | 0.84 | GAA (0.42) | ALDH1A1BTKMAPK1LMNA | |
| SCHEMBL18585911 | 0.84 | GAA (0.42) | ALDH1A1BTKMAPK1LMNA | |
| SCHEMBL490369 | 0.81 | ALDH1A1 (0.51) | ALDH1A1TSHRBTKMAPK1JAK3 | |
| SCHEMBL23683510 | 0.81 | ALDH1A1 (0.51) | ALDH1A1TSHRBTKMAPK1JAK3 | |
| SCHEMBL18585913 | 0.81 | ALDH1A1 (0.51) | ALDH1A1TSHRBTKMAPK1JAK3 | |
| SCHEMBL4866854 | 0.80 | TET3 (0.35) | ALDH1A1TSHRKRASJAK3LMNA | |
| SCHEMBL23683509 | 0.79 | GAA (0.49) | ALDH1A1 | |
| SCHEMBL16385269 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL21879983 | 0.76 | KRAS (0.35) | ALDH1A1FGFR4TSHRKRASBTK | |
| SCHEMBL30089148 | 0.75 | BTK (0.42) | BTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025034858-A1 | FUSED PYRIDINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |